In a milestone for modern medicine, doctors at the Children’s Hospital of Philadelphia and the University of Pennsylvania have successfully treated a newborn, KJ Muldoon, with a tailor-made gene-editing therapy. It’s the first time a customized gene treatment has been administered to a human patient.
A Grim Diagnosis, Few Options
KJ was diagnosed with carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare metabolic disorder that prevents the body from clearing ammonia. Without immediate treatment, ammonia builds to toxic levels, damaging the brain and other organs. Most babies with CPS1 deficiency don’t survive their first week. Traditional care options are limited — often involving liver transplants or palliative support.
Doctors presented KJ’s parents, Kyle and Nicole Muldoon, with two choices: offer comfort care or authorize an experimental treatment never before used in humans.
“We loved him, and we didn’t want him to be suffering,” Nicole Muldoon told The New York Times.
But they also wanted to give him a chance:
The investigators who led the effort to save KJ are presenting their work on Thursday at the annual meeting of the American Society of Cell & Gene Therapy, and are also publishing it in the New England Journal of Medicine.
But KJ’s treatment — which built on decades of federally funded research — offers a new path for companies to develop personalized treatments without going through years of expensive development and testing.
Illnesses like KJ’s are the result of a single mutation — an incorrect DNA letter among the three billion in the human genome. Correcting it requires pinpoint targeting in an approach called base editing.
To accomplish that feat, the treatment is wrapped in fatty lipid molecules to protect it from degradation in the blood on its way to the liver, where the edit will be made. Inside the lipids are instructions that command the cells to produce an enzyme that edits the gene. They also carry a molecular GPS — CRISPR — which was altered to crawl along a person’s DNA until it finds the exact DNA letter that needs to be changed.
Precision Medicine, Fast-Tracked
The Muldoons agreed to pursue this experimental approach known as base editing — a gene-editing technique that rewrites faulty DNA without cutting it. What typically takes years was accomplished in just six months: scientists designed, tested, and administered a gene correction tailored specifically to KJ’s mutation.
Since the therapy, KJ — now just over nine months old — has steadily improved. He’s gaining weight, relying on fewer medications, and showing promising signs of normal development. Though long-term effects are still unknown, early results suggest the treatment is working.
What This Means for the Future
This case signals the beginning of a new chapter in personalized gene therapy. If scaled, it could reshape how the medical field handles not just rare diseases, but eventually common, chronic conditions. Here’s what’s on the horizon:
- Individual Genetic Profiling: Whole genome sequencing could make it possible to create treatments tailored to each patient’s DNA.
- CRISPR Advancements: New gene editors like base and prime editing can precisely fix mutations with fewer side effects.
- Tackling Complex Illnesses: Though most trials today focus on single-gene disorders, future therapies could address multifactorial diseases like diabetes or schizophrenia.
- Epigenetic Control: Instead of permanent edits, future therapies might turn genes on or off temporarily, offering a reversible option for complex conditions.
- Improved Delivery Methods: Next-gen delivery tools, including lipid nanoparticles and viral vectors, could allow in-body editing—streamlining treatment for internal diseases.
- Pre-Symptomatic and Preventive Editing: Early gene testing in newborns or embryos may allow doctors to intervene before disease begins, or even silence high-risk genes.
Ethical and Practical Challenges Ahead
With the science advancing faster than policy, questions of oversight and access are rising. What’s technically possible may soon outpace what’s ethically acceptable. Guardrails will be essential to prevent misuse — such as genetic enhancement — and to ensure treatments don’t become luxuries only the wealthy can afford.
Still, for families like the Muldoons, KJ’s treatment is nothing short of a miracle. For certain inherited conditions — Cystic Fibrosis, Huntington’s Disease, Muscular Dystrophy — gene-editing could shift care from long-term management to potential cures.
This is a breaking news story. Please check back for updates.
READ NEXT: School’s New Deal With Accused Student Sparks Uproar
That is absolutely amazing.